In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone

被引：49

作者：

Park, Hee-Soo

Kim, Hyun-Joo

Seol, Min-Jung

Choi, Dong-Rack

Choi, Eung-Chil

Kwak, Jin-Hwan ^{[1
]}

机构：

[1] Handong Global Univ, Sch Life & Food Sci, Pohang 791708, Kyungbuk, South Korea

[2] Dong Wha Pharmaceut Ind Ltd, Anyang, South Korea

[3] Seoul Natl Univ, Coll Pharm, Seoul, South Korea

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2006年 / 50卷 / 06期

关键词：

D O I：

10.1128/AAC.01407-05

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

DW-224a showed the most potent in vitro activity among the quinolone compounds tested against clinical isolates of gram-positive bacteria. Against gram-negative bacteria, DW-224a was slightly less active than the other fluoroquinolones. The in vivo activities of DW-224a against gram-positive bacteria were more potent than those of other quinolones.

引用

收藏

页码：2261 / 2264

页数：4

相关论文

共 11 条

[1] Adverse drug reactions: implications for the development of fluoroquinolones [J].

Ball, P .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :21-27

[2] High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa:: Results from SENTRY antimicrobial surveillance program, 1998-1999 [J].

Bell, JM ;

Turnidge, JD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :879-881

[3]

Bliss CI, 1985, STAT BIOASSAY

[4] The quinolones: decades of development and use [J].

Emmerson, AM ;

Jones, AM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 :13-20

[5] Vancomycin resistance: Status quo and quo vadis [J].

Endtz, HP ;

van den Braak, N ;

Verbrugh, HA ;

van Belkum, A .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1999, 18 (10) :683-690

[6] Antibacterial resistance worldwide: causes, challenges and responses [J].

Levy, SB ;

Marshall, B .

NATURE MEDICINE, 2004, 10 (12) :S122-S129

[7]

Lode H, 2002, J ANTIMICROB CHEMOTH, V49, P709, DOI 10.1093/jac/dkf024

[8]

*NAT COMM CLIN LAB, 2003, M7A6 NAT COMM CLIN L, V23

[9] In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone [J].

Nilius, AM ;

Shen, LL ;

Hensey-Rudloff, D ;

Almer, LS ;

Beyer, JM ;

Balli, DJ ;

Cai, YN ;

Flamm, RK .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) :3260-3269

[10] In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone [J].

Oh, JI ;

Paek, KS ;

Ahn, MJ ;

Kim, MY ;

Hong, CY ;

Kim, IC ;

Kwak, JH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (06) :1564-1568